Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for P35319

Entry ID Method Resolution Chain Position Source
AF-P35319-F1 Predicted AlphaFoldDB

No variants for P35319

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for P35319

No associated diseases with P35319

3 regional properties for P35319

Type Name Position InterPro Accession
domain DNA binding HTH domain, AraC-type 202 - 300 IPR018060
conserved_site HTH domain AraC-type, conserved site 252 - 294 IPR018062
domain AraC-type transcription regulator, ligand-binding domain 2 - 183 IPR032783

Functions

Description
EC Number
Subcellular Localization
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

No GO annotations of cellular component

Name Definition
No GO annotations for cellular component

2 GO annotations of molecular function

Name Definition
DNA-binding transcription factor activity A transcription regulator activity that modulates transcription of gene sets via selective and non-covalent binding to a specific double-stranded genomic DNA sequence (sometimes referred to as a motif) within a cis-regulatory region. Regulatory regions include promoters (proximal and distal) and enhancers. Genes are transcriptional units, and include bacterial operons.
sequence-specific DNA binding Binding to DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.

No GO annotations of biological process

Name Definition
No GO annotations for biological process

No homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
No homologous proteins
10 20 30 40 50 60
MDPLEDVLTL LKTRSHLSAS LVAGGRWAVR FDAPRVVKFN AVRRGTCQLE VDGIDEPIDL
70 80 90 100 110 120
AEGDCYLLTR PRSFTLRSDP ETAPVDGGVV FARAEDGIAR AGQGDDVFLI GGGFSFGTRA
130 140 150 160 170 180
QELLLDRLPP IVHVPADTPH AETVQWALTA IDQELTHRPM ASTLIAEHLA VIMLVHVLRL
190 200 210 220 230 240
HLERAPHAVS GWLAGLADPV VATALTCLHR DPARSWTVAD LADTAAVSRS TLAARFKATV
250 260 270 280 290 300
GQGPLEYLTR WRIELAARQL REGNATLASI AHSVGYGSES ALSVAFKRVL GMPPGDYRKH
PTMP